Breaking News: Alcon Acquires Neurotech

10/21/26

Hosts: John Kitchens, MD, Scott Krzywonos

 

Topics Covered

 

Alcon Acquires Neurotech for $550 Million

 

Encelto (revakinagene taroretcel-lwey) is the only approved treatment for MacTel 2, with an estimated 25,000 US patients and 2,000-3,000 newly diagnosed annually. It's an OR-delivered encapsulated cell therapy implant requiring surgical expertise, OR relationships, and reimbursement infrastructure. Alcon has all three.

 

Adoption to date: more than 100 surgeries and 700+ patients in the patient portal as of March 2026. Alcon's network is expected to expand the number of centers offering Encelto significantly.

 

Reimbursement: buy-and-bill at approximately $200,000+ is a meaningful risk for surgery centers. Neurotech's specialty pharmacy model removed that risk but limited center economics. Alcon's infrastructure may help centers navigate both pathways.

 

Centers of excellence: neither academic nor private practice dominates. John cites Drew Somerville, MD, a private practice retina specialist in Evansville, Indiana, who built out an Encelto program independently. Alcon can replicate that at scale.

 

Alcon's broader strategy: Lumithera (photobiomodulation), Aurion Biotech (corneal cell therapy), RxSight partnership (light adjustable lens), and now Neurotech, a consistent pattern of investing in disease-specific technology with a procedural delivery component.

 

Brepocitinib / CLARITY (Priovant Therapeutics / Roivant Sciences)

 

Brepocitinib is an oral TYK2/JAK1 inhibitor, 45mg once daily, already approved for psoriatic arthritis. CLARITY is the sNDA program for non-infectious uveitis (NIU).

 

Study design: CLARITY-1 (N=166) and CLARITY-2 (N=204), 48-week double-masked, with a mandatory steroid taper to zero, which is more aggressive than prior NIU trials.

 

Results: cumulative treatment failure at week 48 was 35.4% vs. 78.7% in CLARITY-1 and 32.4% vs. 77.8% in CLARITY-2. Pooled steroid-free quiescence: 62% vs. 20%. Macular edema resolution among patients with baseline ME: 42% vs. 4.8%. Median time to treatment failure not reached in the brepocitinib arm vs. approximately 12 weeks on placebo.

 

Regulatory path: sNDA planned 1H 2027.

 

How it fits with vamikibart: brepocitinib is systemic, offering whole-eye disease control. Vamikibart is intravitreal and targets macular edema specifically. Complementary, not competitive. Patients with refractory macular edema despite systemic control are the logical combination candidates.

 

Key Takeaways

 

Alcon's acquisition of Neurotech gives Encelto the OR infrastructure, relationships, and reimbursement support it needs to scale. Good for patients, and for the long-term viability of a therapy with no real comparator.

 

MacTel 2 is likely underdiagnosed. With Alcon behind the treatment, earlier detection and expanded identification are reasonable expectations.

 

Brepocitinib delivers the strongest uveitis Phase 3 data seen to date: 62% steroid-free quiescence vs. 20% placebo under an aggressive steroid taper. sNDA in 1H 2027.

 

Brepocitinib and vamikibart address different aspects of uveitis and are likely to be used together in difficult patients.

 

Credits

 

Production & Marketing: Laura Brown | Business Operations: Liz Hogan

 

🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube

Previous

Big Pharma’s Retina Bets | Don D’Amico, MD, on BRUNELLO | RetinUp Turns One

Next

Breaking News: LUCIA Misses in Wet AMD — EyePoint Shifts to DME